BiotechTube
Myriamed

Myriamed

Munich, Germany· Est.
myriamed.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

Myriamed GmbH is a Munich/Göttingen-based biotech leveraging advanced 3D human tissue models to de-risk and accelerate early-stage drug development. Its core offering includes high-quality secondary screening services and, more recently, the launch of the myrImager, a high-content analysis platform for engineered tissues. The company operates as a service and technology provider, targeting pharmaceutical and biotech clients to improve the safety and efficacy prediction of new molecular entities before they enter clinical trials.

Medical DevicesDigital Health

Technology Platform

Proprietary human cell and engineered 3D tissue models (e.g., cardiac, skeletal muscle, connective tissue) derived from pluripotent stem cells, combined with the 'myrImager' high-content analysis platform for phenotypic and functional assessment.

Funding History

1
Total raised:$3M
Seed$3M

Opportunities

The growing demand for human-relevant preclinical data to reduce drug development costs and failure rates presents a major opportunity.
The launch of the myrImager creates a scalable product revenue stream alongside its service business.
Innovative projects like MyrSpaceCardio could lead to unique, IP-protected tissue models with superior predictive power.

Risk Factors

The company operates in a competitive market with larger, established players and must convince risk-averse pharmaceutical clients to adopt new technologies.
As a young, private company, it faces financial sustainability risks and dependence on continued funding.
Technological risk remains if its models fail to demonstrate consistent predictive value for human clinical outcomes.

Competitive Landscape

Myriamed competes in the preclinical contract research and complex in vitro model space against larger CROs and specialized organ-on-a-chip companies like Emulate, Mimetas, and CN Bio. Its focus on specific tissue types (cardiac, muscle) and the integrated myrImager system differentiates it, but it must contend with the broader validation and adoption challenges of the entire field.

More companies in Drug Delivery & Formulation →More companies in Germany →